Osteoporotic Fractures

Related by string. osteoporotic fractures * osteoporotic : osteoporotic vertebral compression fractures . osteoporotic vertebral fractures . osteoporotic spines . osteoporotic bone . Osteoporotic . osteoporotic fracture / FRACTURE . fractures . fracture : multiple skull fractures . depressed skull fracture . sustained hairline fracture . hip fracture . Fracture . Fractures * *

Related by context. All words. (Click for frequent words.) 70 Wisconsin Sleep Cohort 70 Health Initiative Observational 68 Canadian Multicentre Osteoporosis 67 Ocular Hypertension Treatment 66 Swedish Mammography Cohort 65 Bankruptcies soar 65 CARDIA 64 Framingham Offspring Study 63 Scandinavian Simvastatin Survival 63 undergoing androgen deprivation 63 Dubbo Osteoporosis Epidemiology 62 ACCORD Eye 62 Framingham Offspring 62 NHANES III 62 Women Ischemia Syndrome 62 Nord Trøndelag Health 62 Prostate Cancer Prevention 61 Sherlock uncovering 61 underwent radical prostatectomy 61 underwent CABG 61 Cancer Prevention ATBC 61 undergone radical prostatectomy 61 Young Adults CARDIA 61 Nutrition Examination 61 Alzheimer Disease Cooperative 61 conducted retrospective cohort 61 serum lipid levels 61 Normative Aging Study 61 running Zutphen Elderly 61 Prepaid Customer Satisfaction 60 prospective multicentre 60 oxycodone CR 60 Insulin Resistance Atherosclerosis 60 Prostate Lung Colorectal 60 Multicenter AIDS 60 Dietary Modification Trial 60 Alpha Tocopherol Beta Carotene 60 relapsed MM 60 Partnership Attitude Tracking 60 Edge STudy 60 Male Ageing 59 Car Naturalistic Driving 59 Home Buyer Seller 59 Memory Study WHIMS 59 RECORD1 59 HYVET 59 Epidemiologic Follow 59 symptomatic BPH 59 aged ≥ 59 Coronary Artery Risk 59 fasting serum 59 limiting generalizability 59 coronary calcification 59 Screening Trial 58 Baseline characteristics 58 HIV seronegative 58 Ischemic Stroke 58 colorectal adenomas 58 Multi Ethnic Study 58 Index CDAI 58 Replication NCS R 58 NHANES #-# 58 Randomized Controlled 58 OPT CHF 58 Comorbidity 58 Acetonide 58 HIV HCV coinfected 58 hip BMD 58 dietary calcium intake 58 longitudinal cohort study 58 CHD mortality 58 osteoporotic fracture 58 Baltimore Longitudinal Study 58 Cognitive Function 58 Atherosclerosis Risk 58 Breakthrough Generations 58 Atherosclerosis MESA 58 Ischemic Heart Disease 58 Digital Mammographic Imaging 58 NLSY 58 Severely Obese 58 Acute Liver Failure 57 asymptomatic PAD 57 SORT OUT III 57 PLCO 57 advanced adenoma 57 undergoing radical prostatectomy 57 Metastatic Prostate Cancer 57 hydroxyvitamin D levels 57 nonfasting triglyceride levels 57 perioperative mortality 57 symptomatic carotid stenosis 57 endometriosis ovarian cysts 57 Bone Fractures 57 nonvertebral fractures 57 Pooled Analysis 57 Skin sterol 57 nulliparous women 57 Nonalcoholic Fatty Liver Disease 57 CHD CVD 57 CARDIA study 57 subclinical hypothyroidism 57 Practice Patterns 57 Prostate Cancer Outcomes 57 sedentary postmenopausal 57 placebo controlled dose escalation 57 Coronary Artery Calcium 57 Vendor Value 57 observational cohort 57 dysglycemia 57 SIMPADICO 57 Low Testosterone 57 nondiabetic patients 57 nondepressed 56 serum selenium 56 Intervention Effectiveness 56 ug dose 56 deep venous thromboses 56 femoral neck BMD 56 Juvenile Idiopathic Arthritis 56 Diabetic Foot Ulcer 56 adjunctive placebo 56 Intervention Trial GAIT 56 Endothelial Function 56 Depressive Symptoms 56 Communities ARIC study 56 MADIT CRT trial 56 Carotid Revascularization Endarterectomy vs. 56 Ovarian PLCO Cancer 56 Glucosamine Chondroitin Arthritis 56 undergone hysterectomies 56 NATRECOR R 56 THIS STUDY analyzed 56 Vertebral Fractures 56 Intervention Trial 56 landmark ATHENA 56 Hormone Refractory Prostate Cancer 56 Folfox 56 Multicenter Phase 56 prostate cancer CaP 56 Spine Patient Outcomes 56 Clinical Antipsychotic Trials 56 Multicentre 56 Prehypertension 56 onset diabetes mellitus 56 prospective observational cohort 56 colorectal neoplasia 56 evaluating mipomersen 56 Dialysis Outcomes 56 Midwinter Bald Eagle 56 Gore REDUCE Clinical 56 atherothrombotic disease 56 Study ARIC 56 CAPRIE 56 Coronary Artery Bypass Graft 56 nondiabetic 56 colorectal adenoma 56 NCCTG N# 56 Evaluation WISE 56 NAMCS 56 Carotid Stenting 56 Operative mortality 56 Nicotine Dependence 56 CRN Sourcing 56 Dunedin Multidisciplinary Health 56 mineral density BMD 56 preintervention 56 MetS 56 Arch Intern Med 56 recurrent venous thromboembolism 56 EURIDIS 56 spontaneous preterm delivery 55 VICTOR E1 55 vitamin D intakes 55 nonpregnant women 55 multicenter placebo controlled 55 PON1 activity 55 Controlled Trial 55 Severe Asthma 55 azilsartan medoxomil 55 postmenopausal hormone therapy 55 Systemic Sclerosis 55 Multicenter 55 REVIVE Diabetes 55 testicular germ cell 55 subtrochanteric 55 dietary questionnaires 55 treatment naive genotype 55 Cardiovascular Risk 55 Invasive Breast Cancer 55 faulty BRCA2 gene 55 LUTS 55 Longitudinal Alcohol Epidemiologic 55 STRIDE PD 55 JAMA. 55 PLX STROKE targeting 55 VADT 55 apo B apo AI 55 clinically localized prostate 55 testosterone supplementation 55 baseline HbA1c 55 postoperative mortality 55 Decompensated Heart Failure 55 underwent bariatric surgery 55 atherogenic dyslipidemia 55 Psychiatric Epidemiology 55 CVD mortality 55 recurrent VTE 55 DCCT 55 Observational Study 55 BR.# 55 Kaiser Permanente Vaccine 55 placebo controlled clinical 55 Meta Analysis 55 Chronic Heart Failure 55 ENESTnd 55 Systolic Hypertension 55 GYTS 55 CR nPR 55 BPH afflicts approximately 55 arterial thickening 55 infliximab monotherapy 55 prospective cohort 55 highest quintile 55 Preterm Birth 55 MSI #F 55 Hemodialysis Patients 55 Oral Fingolimod 55 Screening Trial DMIST 55 CALGB # [002] 55 osteoporotic fractures 55 STEP BD 55 Current Beneficiary 55 Postmenopausal 55 Non Alcoholic Steatohepatitis 55 retrospective cohort 55 registrational Phase 55 Randomized controlled 55 PREZISTA r arm 55 multicenter randomized controlled 55 Functional Outcomes 55 spirometric 55 chronic prostatitis 55 HCV RESPOND 2 55 PCI ExTRACT TIMI 55 Drug Prevents 55 mCRPC 55 multicenter multinational 55 liver transplant recipients 55 mg BID dose 55 biochemical recurrence 55 serum testosterone 55 prospective nonrandomized 55 Artery Disease 55 underwent brachytherapy 55 N telopeptide 55 Kaplan Meier estimates 55 prospective observational 55 Medical Expenditure Panel 55 normotensive 55 controlled multicenter 55 Peripheral arterial disease 55 Complications Trial 55 TAXUS ARRIVE 55 elevated hsCRP 55 Glycemic Control 55 antiretroviral naïve 55 ACTEMRA TM 55 vitamin D inadequacy 55 Randomized Evaluation 55 prospective longitudinal 55 Bogalusa Heart 55 achieved ACR# 55 loop diuretics 55 fragility fractures 55 placebo controlled Phase III 55 Ovarian Cancer Screening 55 del 5q MDS 55 Patient Outcomes 55 waist circumferences 54 baseline FEV 54 Sleep Disturbances 54 vertebral fracture 54 civilian noninstitutionalized population 54 shatters myths 54 BMD measurements 54 myocardial infarctions MIs 54 J Nutr 54 HbA1C levels 54 TAXUS V 54 Colorectal Cancers 54 AIDS Clinical Trials 54 RE LY ® 54 Randomized Controlled Trials 54 Gynecologic Oncology Group 54 Cholesterol Levels SPARCL 54 morphometric vertebral fractures 54 Cardiovascular Outcomes 54 colorectal cancer incidence 54 androgen deficiency 54 nadroparin 54 systolic hypertension 54 MEND CABG 54 J Clin Oncol 54 baseline serum creatinine 54 Diabetes Interventions 54 INTERMAP 54 British Gambling Prevalence 54 #.#mg/dL 54 Earn Less Than 54 venlafaxine XR 54 Communities ARIC Study 54 prospectively defined 54 mean ± SEM 54 venous thromboembolic disease 54 Cancer Incidence Mortality 54 Adenomas 54 EVEREST II 54 Half Assed Network 54 Postmenopausal Women 54 #-# Full Text 54 beta carotene supplementation 54 Study AREDS 54 cerebral infarctions 54 REYATAZ r arm 54 serum vitamin D 54 Calcium Vitamin D 54 BCIRG 54 Professionals Follow 54 ng dL 54 randomized multicenter 54 rape murderAn Alabama 54 cognitively normal 54 Stenting Trial CREST 54 null responder HCV 54 Laryngeal Cancer 54 Non inferiority 54 nonvertebral 54 Arterial stiffness 54 Cognitive Impairment 54 mineral density 54 Therapeutic Effects 54 Heart Failure Patients 54 Randomized Phase 54 adenoma recurrence 54 decompensated liver disease 54 Comorbidities 54 selenium supplementation 54 8mg/kg 54 multicentre prospective 54 Bone Mineral Density 54 MADIT II 54 serum folate concentrations 54 breast cancer recurrences 54 onset atrial fibrillation 54 nmol l 54 subclinical atherosclerosis 54 Aggressive Reduction 54 EDSS score 54 HCV SPRINT 54 serum uric acid 54 thyrotropin levels 54 perioperative complications 54 WHEL 54 laboratory abnormalities 54 Cohort Study 54 Subgroup Analysis 54 Statin therapy 54 tibolone 54 NIDDM 54 multicenter randomized 54 Nymox NX 54 HIV uninfected 54 Prospective Randomized 54 multivariable adjusted 54 HealthGrades analyzed 54 T1DM 54 Trandolapril 54 Prostate Cancer Survival 54 Neuroepidemiology 54 Post Menopausal 54 Free Survival PFS 54 advanced adenomas 54 lifetime abstainers 54 Eye Disease 54 Child Wellbeing 54 postmenopausal women 54 Watchful Waiting 54 Uncontrolled hypertension 54 Body Composition Study 54 Thyroid nodules 54 Randomized Phase II 54 Stroke Risk 54 SPIRIT III 54 Clinical Outcomes Utilizing Revascularization 54 mL/min/#.# m 2 54 Intervention Effectiveness CATIE 54 Lumbar Spine 54 CALGB 54 OSAHS 53 PREZISTA r 53 cTnT levels 53 Antidepressant Use 53 hemoglobin A1c levels 53 plasma selenium 53 Genes Predict 53 Symptom severity 53 Osteoporosis affects 53 ST Segment Elevation 53 Newly Diagnosed Multiple Myeloma 53 telomere lengths 53 ABCSG 53 Liver Disease AASLD 53 Breast Cancer Survival 53 fragility fracture 53 Health Initiative WHI 53 Benign prostatic hyperplasia BPH 53 INSPIRE Trial Phase III 53 advanced neoplasia 53 HORIZONS AMI 53 paclitaxel eluting stents 53 diabetes mellitus DM 53 observational cohort study 53 Prospective Cohort Study 53 distal colon cancer 53 % CI #.#-#.# [003] 53 metabolic syndrome MetS 53 Acute Decompensated Heart Failure 53 nonfasting triglycerides 53 androgen suppression 53 baseline Hb 53 Myocardial Infarction Study 53 knee osteoarthritis 53 placebo dexamethasone 53 adjunctive ABILIFY 53 Primary endpoints 53 Insulin sensitivity 53 heFH 53 Advanced Prostate Cancer 53 RE LY 53 Diabetes Complications 53 antiretroviral naive 53 vulvovaginal atrophy 53 Patient Registry 53 lopinavir r arm 53 plasma homocysteine levels 53 gallstone disease 53 segmented regionally 53 Prostate Disease 53 venous thromboembolism 53 longitudinal observational study 53 Follicular Lymphoma 53 preoperative intraoperative 53 ACUITY trial 53 Urinary Incontinence 53 Prostate Cancer Screening 53 CATIE AD 53 events SAEs 53 impaired fasting glucose 53 ADMIRE HF 53 #:#-#,# CrossRef Medline [002] 53 Exacerbations 53 hemodialysis patients 53 Birth Cohort 53 ANN INTERN MED 53 drank pomegranate juice 53 postmenopausal osteoporotic women 53 retrospective cohort study 53 R# #mg BID 53 Birth Defects Prevention 53 Multiethnic Study 53 Group RTOG 53 serum leptin 53 Taxus Stent 53 underwent prostatectomy 53 Breast Carcinoma 53 Insulin Sensitivity 53 specific antigen PSA 53 Nutritional Status 53 Hip Fracture Risk 53 Prostatitis 53 Subgroup analysis 53 multicentre randomized 53 nonmetastatic prostate cancer 53 adiponectin concentrations 53 Phase III AFFIRM 53 periprocedural MI 53 Stress Incontinence 53 Fibromyalgia Impact Questionnaire 53 Antihypertensive 53 racial disparities persist 53 urinary BPA 53 onset idiopathic hypogonadism 53 Heterozygous Familial Hypercholesterolemia 53 carotid IMT 53 HORIZONS AMI trial 53 APTIVUS r 53 meta regression 53 pre menopausal 53 receiving concomitant corticosteroids 53 Osteoporotic 53 Prostate AdenoCarcinoma Treatment 53 ASCO Breast Cancer 53 Endovascular Valve Edge 53 Hip fracture 53 postmenopausal hormones 53 Unstable Angina 53 NMIBC 53 Benign Prostatic Hyperplasia 53 GH deficiency 53 TIMI Study Group 53 Interpersonal Psychotherapy 53 Related Conditions NESARC 53 Breast Density 53 cerebral microbleeds 53 congenital toxoplasmosis 53 urinary tract symptoms 53 lung esophageal 53 nucleoside naive 53 Genetic Variation 53 Stroke REGARDS study 53 lumbar spine BMD 53 prospective observational studies 53 Cause Mortality 53 Uterine Fibroid Embolization 53 Premenopausal 53 Smoking Linked 53 subanalysis 53 preoperative PSA 53 corrected QT interval 53 BMI z 53 Sleep apnea affects 53 Angiographic 53 perimenopausal women 53 serum folate 53 de novo AML 53 Depressive disorders afflict 53 DCCT EDIC 53 impaired glucose metabolism 53 Prospective Multicenter 53 silent ischemia 53 hemoglobin A1c HbA1c 53 psychiatric comorbidities 53 recurrent malignant glioma 53 hypovitaminosis D 53 histologic subtype 53 treatment naïve genotype 53 retrospective observational study 53 Wactawski Wende 53 BOLDER II 53 obese adolescents 53 CTA# Injection 53 oral antidiabetic medication 53 Debit Issuer 53 severe obstructive sleep 53 carotid stenosis 53 Premenopausal Women 53 EchoCRT 53 Sebastian Schneeweiss 53 asymptomatic carotid stenosis 53 Ophena TM 53 COU AA 53 Osteoarthritis OA 53 Randomized Study 53 MMSE scores 53 Mania Rating Scale 53 underwent liver transplantation 53 psychiatric morbidity 53 CC genotype 53 STRATEGY FOR AN OPEN 53 Suicidal Behavior 53 Levels Linked 53 mcg linaclotide 53 Glucose Metabolism 53 osteoporotic vertebral fractures 52 galiximab 52 Rectal cancer 52 Folic Acid Supplements 52 AIR2 Trial 52 nonobese 52 abdominal adiposity 52 Health Examination Survey 52 Psychiatric Disorders 52 substudy 52 Prostate Cancer Recurrence 52 BRCA2 mutations 52 EQUIP OB 52 Cohort Study MACS 52 Platelet Inhibition 52 XIENCE V demonstrated 52 ICDs implanted 52 oral FTY# 52 Clinical Outcome 52 Multicenter Automatic Defibrillator Implantation 52 PSA nadir 52 Multicenter Trial 52 evaluable subjects 52 MERLIN TIMI 52 cilostazol 52 Stent thrombosis 52 Prolongs Survival 52 premenopausal women 52 suicide attempters 52 carotid atherosclerosis 52 serum PSA 52 coronary revascularizations 52 serum clusterin levels 52 autoantibody positive 52 AVODART 52 Inflammatory Markers 52 prospectively stratified 52 randomized blinded 52 erection hardness 52 Testosterone Therapy 52 Hematologic 52 plasma folate 52 conjugated equine estrogen 52 Stent Thrombosis 52 postintervention 52 Anxiety Depression 52 Renal Cell Carcinoma 52 Nilotinib 52 dosing cohort 52 Sipuleucel T 52 histologically confirmed 52 Stacy Tessler Lindau 52 thromboembolic 52 estimated glomerular filtration 52 Raloxifene STAR 52 Thromboembolic 52 Untreated Syphilis 52 Chronic Constipation 52 VLBW 52 Breast Cancer Mortality 52 Rakai Uganda 52 different sweetener saccharin 52 Nutrition Examination Surveys NHANES 52 lipid elevations 52 Patency 52 elevated LDL cholesterol 52 GRECC 52 CARE HF 52 Nutrition Examination Surveys 52 bioavailable testosterone 52 hip fracture 52 NSTEMI 52 subclinical hyperthyroidism 52 ARB telmisartan 52 Hypertensive 52 BRIM3 52 ACR# ACR# 52 nonrandomized 52 EAT Eating 52 radical prostatectomy RP 52 carotid endarterectomy CEA 52 Pelvic Floor Disorders 52 Charlson comorbidity index 52 See CLINICAL PHARMACOLOGY 52 NCT# ClinicalTrials.gov 52 PRoFESS 52 Psychol Med 52 magnesium intake 52 NHANES surveys 52 noninstitutionalized 52 Surgical Treatment 52 TEAEs 52 Hyperlipidemia 52 Mortality Risk 52 EDSS scores 52 number NCT# ClinicalTrials.gov 52 BRCA2 mutation carriers 52 Crohn Disease Activity 52 Cardiovascular Events 52 2 diabetes T2D 52 beta blocker therapy 52 Carotid Intima Media 52 Cardiovascular Risk Reduction 52 hematological parameters 52 Blood Pressure Monitoring 52 PSADT 52 Aortic stenosis 52 ExTRACT TIMI 52 antidiabetic medication 52 blinded randomized placebo controlled 52 Sleep Disordered Breathing 52 corticosteroid induced 52 ALT elevation 52 Dr. Sudha Seshadri 52 Randomized Trials 52 FluCAM arm 52 BRCA1 mutations 52 CI #.#-#.# [001] 52 estrogen progestin therapy 52 TG MV 52 End Results SEER 52 Hypogonadism 52 REVIVE TA 52 Nesiritide 52 NESARC 52 Secondary efficacy endpoints 52 DAS# scores 52 multicenter randomized clinical 52 CIN2 + 52 NSABP B 52 glucocorticoid induced osteoporosis 52 Cardiac Resynchronization 52 knee OA 52 HbA1c levels 52 MoxDuo TM IR 52 obese postmenopausal 52 Ovary removal 52 uncontrolled hypertension 52 premenopausal 52 REYATAZ r 52 HeFH 52 NNT = 52 Relieve Depression STAR 52 nonsignificant difference 52 symptomatic intracerebral hemorrhage 52 TAXUS VI 52 ARCOXIA 52 virologic response 52 NO# [002] 52 Knee Osteoarthritis 52 Localized Prostate Cancer 52 Hypertrophy 52 Genetic Markers 52 Physical Therapy PTJ 52 Radiation Therapy Oncology 52 postmenopausal 52 baseline A1C 52 tumor histology 52 Infarct 52 International Verapamil SR 52 Sociodemographic 52 Lipid Lowering Treatment 52 neurodevelopmental outcome 52 severe periodontitis 52 blind multicenter 52 double blinded randomized 52 Histologic 52 INTERHEART study 52 diagnostic angiography 52 β blockers 52 JD Power Vehicle Dependability 52 Premenopausal women 52 echocardiographic parameters 52 elevated triglyceride levels 52 Castration Resistant Prostate Cancer 52 Vulnerable Plaque 52 Clinical Remission 52 arterial thromboembolic events 52 multicenter phase 52 HbA 1c levels 52 urate levels 52 Treatment Naive Patients 52 #mg BID [003] 52 CORD II 52 Cholesterol Levels 52 Trial PCPT 52 Advanced Ovarian Cancer 52 prospectively randomized 52 juvenile idiopathic arthritis 52 Cervical Dysplasia 52 habitual snoring 52 Naive Patients 52 Sexual Dysfunction 52 TAXUS ATLAS 52 osteoporotic vertebral compression fractures 52 contralateral breast cancer 52 intravaginal ejaculatory latency 52 Gastric Cancer 52 ELBW infants 52 flutamide 52 Multicenter Study 52 CYPHER Stent 52 ± SD 52 hormone receptor negative 52 Cardiovascular Risk Factors 52 prospective multicenter 52 Venous Thromboembolism 52 transrectal ultrasound guided 52 Munk Olsen 52 vertebral fractures 52 axillary lymph node dissection 52 Netherlands Cohort Study 52 IMPACT DCM 52 BRAF V#E 52 Chronic HCV 52 Testosterone Levels 52 Rating Scale MADRS 52 affective psychosis 52 endometrial hyperplasia 52 Anal cancer 52 lipid lowering medications 52 Hb A1C 52 Ozarelix 52 elevated serum creatinine 52 Associates Vehicle Dependability 51 cardiovascular mortality 51 Abiraterone Acetate 51 BMI ≥ 51 Insulin Therapy 51 postmenopausal hormone 51 Resistant Hypertension 51 definite stent thrombosis 51 NIH CPSI 51 chronic periodontitis 51 CIN3 51 phase IIIb 51 carotid artery intima media 51 kg m² 51 Hip Fracture 51 Beta Blockers 51 Multicenter Randomized 51 unfractionated heparin UFH 51 serum estradiol 51 coronary angiograms 51 Intracranial Aneurysms 51 THIS STUDY 51 pCR 51 Lars Sjostrom 51 stage IIIb IV 51 patients undergoing CABG 51 Clinical Practice Guideline 51 randomized controlled clinical 51 calcium supplementation 51 Outpatient Setting 51 TAVR 51 prostate cancer CRPC 51 ARCALYST ® rilonacept 51 CLA supplementation 51 oophorectomy 51 Thiazolidinediones 51 Echocardiographic 51 Nicotine Addiction 51 bought Glaxo Serevent 51 Lupus Nephritis 51 Urinary incontinence affects 51 Antidepressants Linked 51 Sexual Function 51 CALERIE 51 J Immunol 51 plus methotrexate 51 Nonalcoholic fatty liver 51 CD4 + cell 51 benazepril 51 Secondhand smoke exposure 51 Rheumatoid Arthritis Patients 51 carotid artery stenting CAS 51 highest tertile 51 Female Sexual Function 51 NABE Outlook 51 Aneurysm Repair 51 confidence intervals CIs 51 AVOREN 51 Kaplan Meier 51 chronically immunosuppressed solid 51 Chronic ITP 51 Transgender Discrimination 51 osteopenic 51 noncardiac surgery 51 overt hepatic encephalopathy HE 51 femoral neck fractures 51 NHANES 51 Capacity FVC 51 Kaplan Meier analysis 51 Aggressive Prostate Cancer 51 desvenlafaxine succinate 51 Framingham Heart 51 Pollster Populus interviewed 51 CIMZIA ™ 51 Coronary Prevention 51 Menopausal Symptoms 51 Inflammatory Bowel Diseases 51 Racial Differences 51 hypogonadal 51 Acute Coronary Syndromes 51 LaxPower Forum Poll 51 alfuzosin 51 Val HeFT 51 faulty BRCA genes 51 CYPHER R Sirolimus eluting 51 Osteoarthritis affects 51 Hyperparathyroidism 51 BJU Int 51 Binge Drinkers 51 Psychosomatic Research 51 urinary symptoms 51 Traumatic Encephalopathy CSTE 51 Antiplatelet 51 PRE SURGE 51 Sequenced Treatment Alternatives 51 Primary Mortgage Servicer 51 urinary tract symptoms LUTS 51 RIO Lipids 51 WHIMS 51 Prospective Randomized Trial 51 PCA3 scores 51 Hypoactive Sexual Desire Disorder 51 retrospectively analyzed 51 Cochrane Systematic Review 51 relapsing remitting MS RRMS 51 Renal dysfunction 51 Dr. Sara Forhan 51 adolescent females 51 nonmelanoma skin cancer 51 HRQOL 51 Molecular Genetic 51 atherosclerotic renal artery stenosis 51 Cytogenetic 51 anovulatory infertility 51 Severity Index PASI 51 got Abbott MitraClip 51 multicenter study 51 attain statistical significance 51 TOHP 51 Coronary calcium 51 PsA 51 multicenter 51 Bayer HealthCare Onyx Pharmaceuticals 51 Diabetic Macular Edema 51 variant rs# 51 HCV infected 51 mammographic density 51 bepotastine besilate nasal spray 51 CHAMPION PCI 51 retinal vein occlusion 51 #rd Annual CTRC 51 thrombocytopenic 51 Endothelial function 51 CYP#D# inhibitor 51 LUX Lung 51 serum phosphorous 51 ASCO GU 51 Imaging Biomarkers 51 Relieve Depression 51 umol L 51 distal forearm 51 European Randomized Study 51 prospective randomized placebo 51 serum IGF 51 folate intake 51 Fracture Risk 51 bilateral oophorectomy 51 SHPT 51 Asymptomatic 51 LV dysfunction 51 glycosylated hemoglobin HbA1c 51 Vertebral Fracture 51 Thromboembolism 51 Recurrent Stroke 51 depressive symptomatology 51 genital HSV 51 plasma homocysteine 51 T2 lesions 51 IMPROVE HF 51 HER2 expression 51 Carol Ausborn 51 dalteparin 51 cirrhotic patients 51 symptomatic fibroids 51 Disciple Bible 51 multicenter prospective 51 Fecal Incontinence 51 XIENCE V PROMUS Stent 51 #.#ng/ml 51 Bipolar disorder affects 51 Heather Eliassen 51 controlled dose escalation 51 Osteopenia 51 ORAL Solo 51 #:#-# [019] 51 Malignant Melanoma 51 Gestational Diabetes 51 HPV Infection 51 TMC# C# 51 median CD4 51 ACR# responses 51 Often Misdiagnosed 51 COPAXONE R 51 invasive aspergillosis 51 albumin excretion rate 51 cardiorespiratory fitness 51 Trial NLST 51 Non Alcoholic Fatty 51 Treatment Outcome 51 nontraumatic 51 Obese Teens 51 colorectal cancer CRC 51 #mg BID [001] 51 ACOSOG Z# 51 Phase IIA 51 Lung Cancer Screening 51 nonvertebral fracture 51 singleton pregnancies 51 multicenter randomized double 51 Premature Births 51 Lung Cancer Trial

Back to home page